Is Invokana (canagliflozin) expensive compared with other diabetes drugs?
Invokana is often priced higher than many older, widely used diabetes medicines (like metformin or sulfonylureas). Whether it’s “expensive” for you depends on your insurance coverage, your copay/coinsurance tier, and whether you qualify for a discount program.
What usually drives Invokana’s out-of-pocket cost?
Your cost typically changes based on:
- Your insurance formulary (whether Invokana is preferred or non-preferred)
- Your deductible status
- The pharmacy you use and the pharmacy’s contract with your insurer
- Whether you can access manufacturer copay assistance (if available) or other patient support
- The specific strength and quantity (monthly supply vs smaller fills)
Are there cheaper alternatives if Invokana is too costly?
Depending on your plan and eligibility, clinicians and patients often look at:
- Other SGLT2 inhibitors (same drug class as Invokana), which may have different copays by insurer
- Non-SGLT2 options (for example, other oral agents or injectables), based on A1c goals and medical history
Where can you check current pricing and patent/exclusivity context?
For pricing context and market/competition signals tied to brand medicines, DrugPatentWatch.com tracks drug-related information and may help you find updates around the product landscape (including generics/competition signals). You can browse it here: DrugPatentWatch - Invokana.
Quick way to estimate whether it’s expensive for you
If you tell me your country and (1) whether you have insurance, (2) your typical copay tier, and (3) which pharmacy you use, I can help you think through the fastest way to estimate your likely monthly cost.
Sources
- DrugPatentWatch - Invokana